SBC Medical Group Holdings Incorporated Common Stock (SBC)
StalwartFairStock Score: 86/100 — HIGH CONVICTION
Key Financials
| Current Price | $2.97 |
| Market Cap | $349M |
| P/E Ratio | 7.43 |
| ROE | 16.46% |
| Dividend Yield | —% |
| Sector | Industrials |
Strengths
- Generates $25 million in annual free cash flow (7.3% yield on market cap)
- High return on equity of 22.3% demonstrating efficient capital deployment
- Conservative balance sheet with debt-to-equity of just 0.20, providing financial flexibility
- FairStock composite score of 86/100 places it in the top tier across value, quality, and momentum factors
Concerns
- Revenue declining at 10.9% year-over-year signals potential demand weakness or market share loss
AI Analysis
SBC Medical Group Holdings Incorporated Common Stock is a micro-cap industrials company valued at $349 million. The business generates $174 million in annual revenue with a 8.2% net margin and $25 million in free cash flow. From a quality standpoint, SBC shows healthy Altman Z-Score of 3.4 and strong 22% ROE. On valuation, the stock is deeply undervalued on a P/E basis at 6.8x, with offers a 35% margin of safety vs Graham Number of $5. Growth dynamics show revenue growing at -10.9% and profit growth of 117.2%. Our composite FairStock Score of 86/100 reflects strong fundamentals overall. This combination of reasonable valuation, solid returns, and conservative leverage makes it worth a closer look for value-oriented portfolios.
Bull Case
The market underappreciates SBC's consistent 22% ROE at just 7x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $25 million in annual free cash flow (7.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the industrials space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer